The Goldman Sachs Group Lowers LivaNova (NASDAQ:LIVN) Price Target to $55.00

LivaNova (NASDAQ:LIVN) had its price objective decreased by The Goldman Sachs Group from $64.00 to $55.00 in a research report report published on Monday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

LIVN has been the subject of several other reports. Stifel Nicolaus reduced their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Mizuho cut their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC cut their target price on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Finally, StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova presently has an average rating of “Buy” and an average target price of $62.20.

LivaNova Stock Performance

LIVN stock opened at $40.87 on Monday. The stock has a 50-day moving average price of $47.08 and a 200-day moving average price of $49.43. LivaNova has a 1-year low of $40.37 and a 1-year high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.22 billion, a PE ratio of 97.31 and a beta of 1.10.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. Point72 Asset Management L.P. grew its position in LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after acquiring an additional 806,374 shares in the last quarter. Freestone Grove Partners LP bought a new stake in shares of LivaNova in the fourth quarter worth about $23,102,000. Artisan Partners Limited Partnership bought a new stake in shares of LivaNova in the fourth quarter worth about $21,340,000. The Manufacturers Life Insurance Company grew its stake in shares of LivaNova by 163.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company’s stock worth $25,303,000 after purchasing an additional 339,139 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock worth $34,214,000 after purchasing an additional 328,313 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.